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The Significance of Clinical and Laboratory Features in the 
Diagnosis of Glycogen Storage Disease Type V: A Case Report
Glycogen storage disease type V (GSD-V) is the most common disorder of muscle 
glycogenosis with characteristic clinical and laboratory findings. A 32-yr-old woman 
complained of exercise intolerance and myoglobulinuria since early adolescence. She 
reported several episodes of second-wind phenomenon. Physical examination did not 
show any neurological abnormality, including fixed muscle weakness or atrophy. Serum 
creatine kinase level was 1,161 IU/L at rest. The result of the non-ischemic forearm exercise 
test was compatible with GSD-V. Mutation analysis identified the compound heterozygous 
mutations of the PYGM, p.D510fs and p.F710del, which has not yet been reported in 
Korea. The present case recognizes that detail clinical and laboratory analysis is the first 
step in the diagnosis of GSD-V.
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INTRODUCTION
Glycogen storage disease type V (GSD-V), also known as McAr-
dle’s disease, is the most common disorder of muscle glyco-
genosis (1). GSD-V is caused by alterations in the PYGM which 
encodes myophosphorylase. Myophosphorylase catalyzes the 
phosphorolytic cleavage of glycogen to glucose-1-phosphate in 
skeletal muscle. Therefore, enzyme deficiency results in the de-
fective breakdown of glycogen into glucose and glycogen accu-
mulation in muscle (2).
 GSD-V is inherited in an autosomal recessive pattern, and 
the prevalence has been estimated at about 1 in 100,000-167,000 
(3, 4). Most adult patients present with typical clinical features 
such as exercise intolerance, episodic myoglobulinuria and the 
second-wind phenomenon. In addition, the resting serum cre-
atine kinase (CK) level, forearm exercise test, and electrophysi-
ological studies can contribute to diagnosis. Subsequent muta-
tion analysis and myophosphorylase activity assay can be used 
to confirm the diagnosis.
 There has only been one case report of Korean patients with 
GSD-V (5). However, the previous report did not feature typical 
clinical presentations of GSD-V such as myoglobulinuria and 
the second-wind phenomenon. Here, we report a Korean case 
of GSD-V with typical clinical and laboratory findings.
CASE DESCRIPTION
A 32-yr-old woman (Fig. 1A, II-3) was referred to our clinic due 
to easy fatigability, muscle cramps and myoglobulinuria in June 
2013. Her family history was unremarkable. She recalled easy 
fatigability, muscle cramps and contractures after intense exer-
cise during physical education classes since early adolescence. 
In addition, she had several episodes of dark urine following in-
tense exercise such as long-distance running. These symptoms 
of exercise intolerance had been aggravated one year before. 
She also reported marked improvement in exercise tolerance 
after about 20 min, a process termed the ‘second-wind phe-
nomenon’; specifically, she had seen improvement in excessive 
fatigue, breathlessness, and tachycardia. Physical examination 
did not show fixed muscle weakness and muscle atrophy. All of 
her sensory modalities and tendon reflexes were intact. Labo-
ratory studies revealed a serum creatine kinase (CK) level of 
1,161 IU/L (normal < 215 IU/L) at rest. Nerve conduction study 
(NCS) and needle electromyography study (EMG) did not show 
any abnormalities at rest. The non-ischemic forearm exercise 
test showed no increase in venous lactate level with a normal 
increase in ammonia (Fig. 2). To confirm easy fatigability and 
weakness after exercise, we performed motor NCS on the ulnar 
nerve after voluntary maximal contraction for two minutes and 
50 Hz nerve stimulations for one second. However, the ampli-
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tudes of the compound muscle action potentials did not de-
crease after maximal contraction and nerve stimulation. In ad-
dition, EMG did not show silent electrical activities during mus-
cle cramps. Based on the clinical and laboratory features, she 
was diagnosed with glycogenoses with exercise-induced weak-
ness, especially GSD-V. Therefore, we performed PYGM geno-
typing. 
Mutational analysis 
A DNA sample was extracted from peripheral leukocytes using 
the Quick Gene blood kit (Fujifilm, Tokyo, Japan). The primer 
set that covers all 20 exons and their flanking intron regions of 
the PYGM was designed with Primer 3web v.4.0 (http://prim-
er3.wi.mit.edu/) using sequences from the Gen Bank accession 
number NT_167190.1. All the exons of the PYGM were sequenc-
ed using BigDye Terminator v.3.1 (Applied Biosystems, Foster 
City, CA, USA) followed by polymerase chain reaction. Electro-
phoresis and analysis of the reaction mixtures were done with 
ABI3130xl Genetic Analyzer (Applied Biosystems). A compound 
heterozygous mutation was identified; one allele had a frame-
shift mutation of c.1531delG (p.D510fs) in exon 13 and the other 
allele had a deletion mutation of c.2128_2130delTTC (p.F710del) 
in exon 17 (Fig. 1B). These mutations have been previously re-
ported to be underlying causes of GSD-V in Japanese patients (6).
DISCUSSION
We described a Korean patient with PYGM mutations who had 
typical clinical and laboratory findings for identification of GSD-
V. Even though GSD-V is the most common disorder of muscle 
glycogenosis, our patient is only the second case of genetically 
proven GSD-V in Korea.
 Four characteristic clinical features are important for initial 
suspicion of GSD-V. First, exercise intolerance such as easy fati-
gability, muscle cramps and contractures is triggered by static 
contractions and dynamic exercise. Almost all patients are ad-
mitted to the hospital for exercise intolerance. The pathophysi-
ology of exercise intolerance is not fully understood, but may be 
associated with impaired glycolysis (2). A deficient glycogen-
dependent adenosine triphosphate (ATP) supply might result 
in down-regulation of Na+/K+ pumps in myocytes, leading to 
loss of membrane excitability (7, 8). The defective breakdown of 
glycogen into glucose is reproduced by the forearm exercise test. 
The forearm exercise test showed no increase in lactate level 
with a normal increase in the ammonia level. The forearm ex-
ercise test was originally carried out under ischemic conditions; 
however, we did not conduct the test under ischemic conditions 
because the diagnostic value is just as good in non-ischemic 
conditions and muscle injury can be avoided (9). In addition, 
several previous studies demonstrated loss of membrane excit-
ability as the amplitude of CMAPs decreased after maximal 
contracture and high frequency repetitive nerve stimulation, 
and silent electrical activities during muscle cramping (10, 11). 
However, we did not identify these findings in the patient pre-
sented in this case study. It may be associated with benign clini-
cal symptoms without fixed muscle weakness.
 Second, the serum CK level is elevated in almost all patients 
Fig. 1. Pedigree and Sequencing chromatograms in Korean patient with PYGM muta-
tions. (A) Pedigree of a family with glycogen storage disease type V (GSD-V). Arrow 
indicates the proband, whose DNA was used for direct sequencing of PYGM. Filled 
symbol indicate affected member. (B) Sequencing chromatograms of PYGM mutations. 
One allele had a frameshift mutation of c.1531delG (p.D510fs) in exon 13 and the 















Fig. 2. Non-ischemic forearm exercise test in a patient with GSD-V. The non-ischemic 
forearm exercise test showed no increase in venous lactate level with a normal in-
crease in ammonia.
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with GSD-V even in the absence of exercise. One recent report 
indicated that hyperCKemia (> 200 IU/L) was present in 99% of 
patients and the majority (79%) of patients had a level greater 
than 1,000 IU/L (4). The elevation of serum CK level at rest is 
likely associated with muscle damage due to impaired glycoly-
sis during exercise. However, the serum CK level at rest did not 
correlate with clinical severity because exercise-induced mus-
cle damage can stimulate muscle repair and adaptive hypertro-
phy (12). In addition, one study demonstrated no significant 
difference in serum CK level at rest between physically active 
and inactive patients (4). 
 Third, about half of all patients with GSD-V have experienced 
one or more episodes of hyperCKemia (several thousand IU/L) 
or myoglobulinuria after intense exercise. In addition, about 
50% of patients with myoglobulinuria develop acute renal fail-
ure, which is almost always reversible, but nevertheless requires 
emergency treatment (13).
 Fourth, the second-wind phenomenon, an especially unique 
feature of GSD-V, differentiates GSD-V from other muscle gly-
cogenoses such as muscle phosphofructokinase deficiency 
(13). This phenomenon is reported by almost patients during 
the medical interview. If it is not found in the medical history, it 
is easily reproduced by diagnostic cycle test (14). Therefore, it is 
the key finding that leads to initial suspicion of GSD-V. This 
phenomenon is caused by an increased supply of glucose and 
free fatty acids after a long period of exercise. These changes 
lead to a switch in metabolic pathways from endogenous glyco-
genolysis to oxidative phosphorylation of blood-borne fatty ac-
ids (15). However, continuing to exercise also results in severe 
muscle cramps and myoglobulinuria. 
 Besides these major clinical features, some patients with GSD-
V can also show fixed muscle weakness. Most patients includ-
ing the patient in this report did not complain of muscle weak-
ness, but approximately one-third of patients develop proximal 
muscle weakness with aging (2, 16).
 Mutation analysis and the myophosphorylase activity assay 
are used to confirm the diagnosis of GSD-V; however, molecu-
lar analysis is more important and more commonly used be-
cause muscle biopsy is needed for the enzyme activity assay. At 
last count in February 2013, 131 different mutations have been 
reported in the human gene mutation database (http://www.
hgmd.org). Genotype has not been correlated with the severity 
of clinical phenotype in previous studies (17, 18). However, there 
has been a higher incidence of some genotypes in specific eth-
nic groups; for example, p.R50X and p.G205S in the white pop-
ulation, p.F710del in the Japanese population, and p.W798R in 
the Spanish population (13). Likewise, two mutations in our 
patient have previously been reported in Japan, a neighboring 
country of Korea (6). In particular, the p.F710del mutation has 
been identified in 73% of Japanese patients (19).
 In conclusion, we identified a compound heterozygous mu-
tation of the PYGM in a Korean patient with typical clinical and 
laboratory findings. We recognize that detailed clinical and lab-
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